ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Share Price Pass Above Fifty Day Moving Average – Should You Sell?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)’s stock price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $102.71 and traded as high as $125.76. ProShares Ultra Nasdaq Biotechnology shares last traded at $125.19, with a volume of 9,769 shares changing hands.

ProShares Ultra Nasdaq Biotechnology Stock Performance

The company has a market capitalization of $99.75 million, a price-to-earnings ratio of 20.68 and a beta of 1.20. The company has a 50-day moving average price of $103.49 and a 200-day moving average price of $90.04.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. acquired a new position in ProShares Ultra Nasdaq Biotechnology during the second quarter valued at approximately $32,000. Citadel Advisors LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology in the third quarter worth $307,000. Finally, Kaizen Financial Strategies raised its holdings in ProShares Ultra Nasdaq Biotechnology by 4.7% in the first quarter. Kaizen Financial Strategies now owns 5,565 shares of the exchange traded fund’s stock worth $483,000 after purchasing an additional 250 shares during the period.

About ProShares Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.